Convergent evolution dictates that diverse groups of viruses will target both similar and distinct host pathways to manipulate the immune response and improve infection. In this study, we sought to ...
EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials
SAB Biotherapeutics Inc SABS has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176. It has recently received FDA Breakthrough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback